Orion OYJ (OTCMKTS:ORINY – Get Free Report) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “strong-buy” rating in a report released on Monday, Zacks reports.
Orion OYJ Stock Down 1.9%
Shares of ORINY stock opened at $54.77 on Monday. Orion OYJ has a 52-week low of $30.89 and a 52-week high of $55.85. The firm’s 50-day moving average is $47.15 and its 200-day moving average is $41.36.
Orion OYJ Company Profile
Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.
The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.
Founded in Finland in 1917, Orion is headquartered in Espoo.
Featured Stories
- Five stocks we like better than Orion OYJ
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Orion OYJ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion OYJ and related companies with MarketBeat.com's FREE daily email newsletter.
